カーボプラチン,エトポシド,ダーヴァルマブを小細胞膀がんの治療における新補助療法として新規使用
Victoria Gonzalez1, Edward Linton2, Timothy Boyce2
1Department of Urology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USA.
Urology case reports
|September 2, 2025
まとめ
この研究は,小細胞性膀がん (SCCB) の新種の新補助化学療法と免疫療法を強調しています. 治療は完全な反応を示したが,珍しい網膜症の合併症が発生した.
科学分野:
- 腫瘍学
- 泌尿器がん
- 癌 の 治療
背景:
- 小細胞性膀がん (SCCB) は,まれで攻撃的な悪性腫瘍である.
- 通常,SCCBの管理にはマルチモダルの治療が必要です.
さらに関連する動画
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
14.8K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.4K
関連する概念動画
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659